New cocktail approach targets hard-to-treat pancreatic cancer

NCT ID NCT04753879

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests a low-dose combination of five chemotherapy drugs (gemcitabine, nab-paclitaxel, capecitabine, cisplatin, irinotecan) followed by two maintenance drugs (olaparib and pembrolizumab) in 38 people with untreated metastatic pancreatic cancer. The goal is to see if this approach can slow cancer growth and control the disease longer than current treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Gemcitabine, nab-paclitaxel, capecitabine, cisplatin, irinotecan, olaparib, pembrolizumab
What this could lead to
If successful, this could offer a new treatment option that delays cancer progression in people with metastatic pancreatic cancer.
What could go wrong
This is a small, early-phase trial (38 people) with no control group. The combination has significant side effects, and it may not improve survival or be better than standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Sidney Kimmel Comprehensive Cancer Center

    Baltimore, Maryland, 21231, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.